Weight loss is known to improve markers of fatty liver disease but authors of a recent meta-analysis took their investigation deeper. Scan through the research to the findings.
In the absence of pharmacotherapies for nonalcoholic fatty liver disease (NAFLD), weight loss is the primary intervention recommended and is known to be successful, with greater weight reduction associated with greater improvements in a range of disease markers.
Against this background, authors of a meta-analysis published recently in Metabolism Clinical and Experimental looked further to identify the relationship between magnitude of weight loss and improvements in NAFLD. We break down the study for easy-reading in the slides that follow.
Slide image ©Kateryna_Kon/stock.adobe.com